Inés Modrego Pardo

Inés Modrego Pardo

Auto-generated profile, based on publicly available information

Inés Modrego Pardo

Endocrinology and Nutrition Department, Marina Baixa Hospital, Villajoyosa, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
OMOscar Moreno-Perez
Oscar Moreno-Perez
RRRebeca Reyes-Garcia
Rebeca Reyes-Garcia
IMInés Modrego‐Pardo
Inés Modrego‐Pardo
VDViyey Kishore Doulatram-Gamgaram
Viyey Kishore Doulatram-Gamgaram
CCCarlos Casado Cases
Carlos Casado Cases
TAThe Seen Diabetes Area
The Seen Diabetes Area

21 February 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
OMOscar Moreno-Perez
Oscar Moreno-Perez
RRRebeca Reyes-Garcia
Rebeca Reyes-Garcia
IMInés Modrego-Pardo
Inés Modrego-Pardo
MLMarina López-Martínez
Marina López-Martínez
MSMaria Jose Soler
Maria Jose Soler
We are entering a new era in the management of adiposity-based chronic disease (ABCD) with type 2 diabetes (T2D) and related chronic kidney disease (CKD). ABCD, T2D and CKD can affect almost every major organ system and have a particularly strong impact on the incidence of cardiovascular disease (CVD) and heart failure. ABCD and the associated insulin resistance are at the root of many cardiovascular, renal and metabolic (CKM) disorders, thus an integrated therapeutic framework using weight loss (WL) as a disease-modifying intervention could simplify the therapeutic approach at different stages across the lifespan. The breakthrough of highly effective WL drugs makes achieving a WL of >10% possible, which is required for a potential T2D disease remission as well as for prevention of microvascular disease, CKD, CVD events and overall mortality. The aim of this review is to discuss the link between adiposity and CKM conditions as well as placing weight management at the centre of the holistic CKM syndrome approach with a focus on CKD. We propose the clinical translation of the available evidence into a transformative Dysfunctional Adipose Tissue Approach (DATA) for people living with ABCD, T2D and CKD. This model is based on the interplay of four essential elements (i.e. adipocentric approach and target organ protection, dysfunctional adiposity, glucose homeostasis, and lifestyle intervention and de-prescription) together with a multidisciplinary person-centred care. DATA could facilitate decision-making for all clinicians involved in the management of these individuals, and if we do this in a multidisciplinary way, we are prepared to meet the adipocentric challenge.

11 July 2025 in Clinical Kidney Journal
Verified
Journal Article
Open access
OMOscar Moreno-Perez
Oscar Moreno-Perez
RRRebeca Reyes-Garcia
Rebeca Reyes-Garcia
CGCristina Guillen-Morote
Cristina Guillen-Morote
VDViyey Kishore Doulatram-Gamgaram
Viyey Kishore Doulatram-Gamgaram
CCCarlos Casado Cases
Carlos Casado Cases
IMInés Modrego-Pardo
Inés Modrego-Pardo
Background: Subcutaneous semaglutide has shown kidney-protective effects in people with type 2 diabetes (PWT2D), but data on oral semaglutide remain limited. This multicenter real-world study evaluates the clinical effectiveness of oral semaglutide on kidney outcomes in PWT2D. Methods: We included PW2TD aged ≥18 years who initiated oral semaglutide in routine practice between 2021 and 2022 in the Spanish National Health System, with at least one report of clinical follow-up (FU) data at 3 months. Co-primary endpoints were changes in urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) slope at 6-12 months. We also assessed baseline predictors of response, drug persistence, and safety by CKD severity. Results: Data were available for 819 PWT2D (median age 63 years, eGFR 88.1mL/min/1.73m2, UACR 12 mg/g, 45.8% female), median FU was 8.96 months. Oral semaglutide reduced UACR by 30.3% and 40.0% in the overall cohort, by 40.2% and 50.7% in those with a UACR ≥ 30 mg/g, and by 40.6% and 49.9% in those with a UACR ≥ 300 mg/g at 6 and 12-months FU, respectively. PWT2D with a low age-adjusted risk of liver fibrosis by the FIB-4 index had increased odds of achieving a >30% reduction in UACR (aOR 5.50 [95%CI 1.6-18.7]) regardless of baseline background. Metabolic and weight loss effectiveness, safety and persistence of oral semaglutide were consistent across CKD severities. Conclusions: In a real-world setting, oral semaglutide treatment for up to 52 weeks resulted in clinically meaningful reductions in albuminuria without changes in eGFR slope in PWT2D. Effectiveness, safety and tolerability were not influenced by CKD severity.

1 May 2021 in Endocrinología, Diabetes y Nutrición
Verified
Journal Article
Closed access
IPInés Modrego Pardo
Inés Modrego Pardo
MBMarcelino Gómez Balaguer
Marcelino Gómez Balaguer
FMFelipe Hurtado Murillo
Felipe Hurtado Murillo
ENEnrique Cuñat Navarro
Enrique Cuñat Navarro
EIEva Solá Izquierdo
Eva Solá Izquierdo
CACarlos Morillas Ariño
Carlos Morillas Ariño

17 July 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
RRRebeca Reyes-Garcia
Rebeca Reyes-Garcia
OMOscar Moreno-Perez
Oscar Moreno-Perez
CGCristina Guillen-Morote
Cristina Guillen-Morote
IMInés Modrego-Pardo
Inés Modrego-Pardo
VDViyey Kishore Doulatram-Gamgaram
Viyey Kishore Doulatram-Gamgaram
OAOn Behalf Of The Seen Diabetes Area
On Behalf Of The Seen Diabetes Area
Background: Sex differences in type 2 diabetes (T2D) are a growing area of diabetes research. No data have been reported on sex differences with oral semaglutide (oSEMA) in a real-world setting. Methods: We included people with T2D who started treatment with oSEMA in routine clinical practice between November 2021 and November 2022, with at least one report of clinical follow-up (FU) data at 3 months. We evaluated in women with T2D (WWT2D) the clinical effectiveness of oSEMA and factors associated with clinical response and persistence. We also analyzed differences in baseline characteristics, clinical effectiveness, persistence rates and safety according to biological sex. Results: Of the 1018 subjects [median age: 63 years, body mass index (BMI): 33.8 kg/m2, HbA1c: 7.8%], 469 were WWT2D. In WWT2D, oSEMA reduced HbA1c by 0.7% [−0.1 to −1.3] and 0.9% [−0.2 to −1.5] at the 6- and 12-month FU visits, while weight decreased by 4.6% [2.0 to 7.9] and 7.2% [2.5 to 10.9], respectively. Weight loss was >10% in 29.8% of WWT2D (95% CI 25.8 to 34.1); meanwhile, the combined endpoint (HbA1c decrease ≥ 1% + weight reduction ≥ 5%) was achieved in 23.5% (95% CI 19.8 to 27.5%) of WWT2D at the 12-month FU visit. Achievement of glycaemic targets was similar in women and men (59.3% vs. 61.1%). We found no sex differences in weight loss (6.9% vs. 6.8%), oSEMA maintenance dose, persistence rate (76.3% vs. 77.3%), or adverse events. Conclusions: oSEMA was effective and safe in WWT2D in a real-world setting, with nearly one-third of patients reporting weight loss >10% and more than two-thirds achieving HbA1c < 7%. oSEMA showed no sex bias in terms of effectiveness and safety.

1 August 2020 in Endocrinología, Diabetes y Nutrición
Verified
Journal Article
Closed access
IMInés Modrego-Pardo
Inés Modrego-Pardo
ESEva Solá-Izquierdo
Eva Solá-Izquierdo
CMCarlos Morillas-Ariño
Carlos Morillas-Ariño